Immunome Inc
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | |
| – | +18.0% | +22.8% | +0.0% | -16.4% | +15.4% | +188.7% | +40.6% | |
| – | +27.3% | +4,335.7% | +455.2% | +54.6% | +16.7% | +153.1% | +63.1% | |
| – | -15.0% | +36,117.6% | -52.1% | +80.6% | – | – | – | |
| – | – | -670.3% | – | -19.3% | +434.9% | +24.0% | -202.4% | |
| – | +2.2% | +151.5% | -86.5% | +213.9% | +235.1% | +6,339.0% | -81.9% | |
| – | +2.2% | +151.5% | -86.5% | +213.9% | +12,191.9% | +179.0% | – | |
| – | – | -98.9% | – | – | – | – | – | |
| – | – | +40.0% | – | – | – | – | – | |
| – | +11.1% | – | -330.6% | – | – | – | – | |
| – | – | +363.6% | -44.4% | -99.9% | +363,675.0% | +106.6% | +166.2% | |
| – | – | +3,855.7% | -74.6% | -405.5% | – | -43.0% | +1,042.2% | |
| – | – | – | – | – | – | – | – |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.